股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 143,000,000,000 | | USD | | 0.001 USD | | 143,000,000 | | 增加 / 減少 (-) | | | | 0 | | USD | | | | 本月底結存 | | 143,000,000,000 | | USD | | 0.001 USD | | 143,000,000 | | 2. 股份分類 | 其他分類 (請註明) | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | ...

Core Insights - Deep Longevity, Inc is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1] - Deep Longevity aims to establish a local sales team in the U.S. to drive partnerships with various health-related entities [2] Group 1 - Deep Longevity's expansion into the U.S. is a significant milestone, with plans to capture a share of the $6.8 trillion health market [1][2] - The aging clocks developed by Deep Longevity include BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, providing personalized insights for consumers and healthcare providers [1][2] - The company has received support from numerous peer-reviewed papers and patents for its technology, which integrates various biological and psychological factors [2][3] Group 2 - The initial sales focus will be on the Southeastern U.S., including states like Alabama, Florida, and Georgia, with plans to build high-impact partnerships [2] - Deep Longevity's technology offers a vertical software as a service (SaaS) solution that provides personalized recommendations to improve health and extend healthy lifespan [3]

Core Viewpoint - Deep Longevity, Inc. plans to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2]. Group 1: Expansion Plans - Deep Longevity will establish a local sales team in the U.S., with the first two sales personnel joining on January 1, 2026 [2]. - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2]. Group 2: Product Offerings - The company offers clinically validated aging clocks, including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, which provide multi-dimensional biological age assessments beyond chronological age [1][2]. - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, integrating blood biomarkers, epigenetics, psychology, and biology to deliver comprehensive biological aging profiles [2]. Group 3: Business Model - Deep Longevity provides vertical software-as-a-service (SaaS) solutions that offer personalized recommendations to improve health and extend healthy lifespan [3].

（於開曼群島註冊成立之有限公司） （股份代號：���） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Deep Longevity, Inc（本公司之全資附屬公司）連同其附屬公司研發在分子、細 胞、器官及心理層面追蹤人類老化的可解釋之人工智能系統。Deep Longevity的 專利深層老化時鐘為消費者、醫生及企業提供垂直型軟件即服務(SaaS)©解決方 案，提供經證實可改善健康狀況並延長健康壽命的個人化建議。更多資訊請瀏覽 www.deeplongevity.com。 自願性更新營運情況 Deep Longevity於二零二六年第一季度戰略進駐美國市場 本公佈乃勵晶太平洋集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）按自願基準而作出，以知會本公司股東及潛在投資者下列 有關其營運的最新情況。 本公司今日宣佈，全球可解釋人工智能驅動老化時鐘與長壽科學的領導者Deep Longevity, Inc及其附屬公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勵晶太平洋集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | 本月底結存 | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 2. 股份分類 | 其他分 ...

截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 143,000,000,000 | USD | | 0.001 | USD | | 143,000,000 | | 2. 股份分類 | 其他分類 ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號：575) NOTIFICATION LETTER 通知信函 23 September 2025 Dear Non-registered Shareholder(s)(Note 1), Regent Pacific Group Limited (the "Company") － 二零二五年中期報告（「是次公司通訊」）之發佈通知 是次公司通訊之中、英文版本已上載於本公司網站(www.regentpac.com)及香港聯合交易所有限公司披露易網站(www.hkexnews.hk)，歡迎查閱。 – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication is available ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號：575) NOTIFICATION LETTER 通知信函 23 September 2025 Yours faithfully, For and on behalf of Regent Pacific Group Limited Jamie Gibson Executive Director Dear Registered Shareholder(s), Note: Corporate communications refer to all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) annual and interim reports (and all reports and financial statem ...

CONTENTS 目錄 • A reduced loss attributable to shareholders of the Company of approximately US$2.22 million, which was mainly attributable to the Group's operating and R&D expenses of approximately US$2.25 million. • In respect of the progress being made with Senstend™ in the PRC, the main objective remains for Wanbang Biopharmaceutical to obtain marketing approval by the end of 2025, with first commercial launch projected to start in Q1 2026. If the NMPA grants an import licence for Senstend™, US$5 million ( ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勵晶太平洋集團有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | 143,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | 本月底結存 | | | 143,000,000,000 | USD | | 0.001 USD | | 143,000,000 | | 2. 股份分類 | 其他分類 ...